This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Founded in Pavia, Italy, SEA Vision Group has become a leader in the construction of traceability, data collection, and inspection systems in the pharmaceuticals and cosmetics packaging sector.
By strategic choice of Marchesini Group, and in accordance with its usual policy, the new corporate structure will not interfere with the expansion plan of SEA Vision Group, which is forecasting a turnover of over 50 million Euro for 2022.
“We have been engaging with Industry 4.0 issues for over 20 years, since well before they became a hot topic,” commented Pietro Cassani. “SEA Vision Group’s entry into the Marchesini Group will enable us to create packaging lines that are even more integrated with vision and inspection systems, to guarantee our customers ever-improving performances and a high degree of personalisation.”
“After years of strategic partnership, today we are completing our entry into the Marchesini Group, this operation will ensure SEA Vision Group the best conditions for growth on the international markets, and further boost our already strong development ambitions,” pointed out Michele Cei, CEO of SEA Vision Group. “All the projects on which we are hard at work to launch new products with AI techniques, such as line clearance, or in the areas of vision and traceability, will continue with even greater drive. We will also retain our commercial independence – in other words, our identity.”
“Through in-house management of the complex dynamics involved in the digitalisation of production processes, we intend to interconnect mechanical engineering with robotics and software, and manufacturing with digitalisation and AI,” commented Maurizio Marchesini, Chairman of Marchesini Group and Vice-Chairman of Confindustria responsible for Supply Chains and Medium-Sized Enterprises.
“The aim is to transform the production lines which package, amongst other things, products like Covid vaccines and cancer drugs, into objects which can be entirely interconnected, in order to offer our customers real-time technical service in line with the highest standards required by the industries in which we work.”